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Abstract
Background: TGF-β is induced in the vasculature with aging suggesting that high plasma TGF-β levels may be a
risk factor for chronic kidney disease (CKD) in older adults.
Methods: We conducted a cross-sectional analysis of the association between plasma TGF-β levels and CKD including
data for 1722 older adults who had participated in the 1996/97 visit of the Cardiovascular Health Study (CHS). Prevalent
CKD was defined as eGFR < 60 mL/min/1.73 m2 or urinary albumin/creatinine ratio (ACR) ≥30 mg/g. We also evaluated
whether baseline TGF-β levels predicted change in eGFR, cardiovascular (CV) events, or mortality in longitudinal
analysis.
Results: Plasma TGF-β levels were significantly and independently associated with lower eGFR in cross-sectional
analysis. Doubling of TGF-β was significantly associated with lower eGFR (β estimate after adjusting for CV risk
factors = −1.18, 95% CI −2.03, −0.32). We observed no association with albuminuria. There was no association between
baseline TGF-β and change in eGFR, but each doubling of TGF-β at baseline was associated with increased risk of a
composite outcome of CV events and mortality, adjusted HR 1.10 (95% C.I. 1.02– 1.20, p = 0.006).
Conclusion: In this large cohort of community-dwelling older individuals, high plasma TGF-β levels are modestly, but
independently associated with lower eGFR but not with albuminuria in cross-sectional analysis. In addition, TGF-β levels
are associated with increased risk of CV events and mortality. Further research is needed to determine the direction of
association between plasma TGF-β and the risk of CKD and CKD-associated morbidities in older adults.
Keywords: CKD, TGF-β, GFR, Older adults
Background
In the United States, chronic kidney disease (CKD)
prevalence is estimated to afflict approximately 11.5% of
the adult population [1]. The pathophysiology of CKD
differs depending on the primary cause of kidney injury.
However, kidney disease progression, independent of the
type of primary insult, occurs via a final common path-
way of glomerulosclerosis and tubulointerstitial fibrosis
[2]. The kidney responds to injury by releasing pro-
inflammatory cytokines and growth factors such as
transforming growth factor (TGF)-β. Sustained overex-
pression of TGF-β from continuous injury induces extra-
cellular matrix accumulation in the diseased kidney [3]
and ultimately leads to glomerular and tubulointerstitial
fibrosis [4–6]. The role of TGF-β in kidney disease pro-
gression is further affirmed by data that administration
of anti-TGF-β antibody attenuates fibrosis in different
animal models of kidney injury indicating an important
role of TGF-β in the fibrotic process [7–9]. Furthermore,
several clinical studies have shown increased TGF-β
expression in the kidneys of patients with glomerular
disease including diabetic nephropathy [10, 11] and
other inflammatory glomerulonephritides [12, 13].
Despite the established role of TGF-β in kidney disease
progression in animal models, it remains unclear
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whether systemic TGF-β levels indicate kidney disease in
humans. Some studies that have measured plasma levels
of TGF-β in persons with diabetic kidney disease [14, 15]
suggest that increased TGF-β levels predict progressive
kidney disease in this patient population. In contrast to
these findings, an analysis in the Chronic Renal Insuffi-
ciency Cohort study evaluated TGF-β levels in 3791
participants, almost half of whom had DM, and found no
cross-sectional association between TGF-β levels and
measures of CKD [16]. Thus, whether or not TGF-β levels
are a risk factor for CKD in general remains uncertain.
CKD is more prevalent in the older population [1, 17],
mainly owing to reduced eGFR rather than albuminuria
[18]. Aging itself appears to associate with a higher
prevalence of fibrotic kidneys [19]. The high prevalence
of CKD in older adults is attributable not only to the
presence of traditional risk factors such as diabetes and
hypertension but may also be the result of age-related
functional changes that occur in the kidney [20]. Import-
antly, epidemiological studies have identified arterial
stiffness (which increases with age) as a predominant
risk factor for progressive GFR decline in older people
[21, 22]. We have previously shown TGF-β levels inde-
pendently predict peripheral vascular disease in aged
community-dwelling adults [23]. These findings are con-
sistent with data that TGF-β is induced in the arterial
wall with aging [24], such that apart from TGF-β
production and its effects at the level of the nephron,
upstream vascular generation could contribute to circu-
lating TGF-β levels in older individuals. To our know-
ledge, no study has examined the potential association
between plasma TGF-β levels and CKD in an older,
community-living population. The Cardiovascular
Health study (CHS) is a large observational cohort of
community-dwelling adults aged ≥65 years that was
designed to study traditional and novel risk factors for
cardiovascular disease in older adults. Circulating TGF-β
levels were measured on platelet-free plasma in a subset
of CHS participants at the 1996/97 study visit in
addition to estimated glomerular filtration rate (eGFR)
and urinary albumin/creatinine ratio (ACR). Thus, we
utilized cross-sectional data from CHS to test our hy-
pothesis that higher plasma TGF-β levels associate with
prevalent kidney disease in community-living older per-
sons. We also evaluated whether TGF-β levels associated
with longitudinal outcomes including change in eGFR,
cardiovascular events, and mortality.
Methods
Study participants
The details of the study design, rationale, and study popu-
lation of CHS have been described previously [25, 26].
Briefly, CHS is a community-based prospective cohort
study designed to explore cardiovascular disease risk
factors and stroke in individuals 65 years or older. The
original cohort of the CHS consisted of 5201 participants
who were randomly enrolled from the Medicare-eligibility
lists in 4 US communities (Forsyth County, NC;
Sacramento County, CA; Washington County, MD; and
Allegheny County, PA) in 1989 to 1990. A supplemental
cohort of 687 mostly African-American participants was
recruited in 1992–1993.
The eligible individuals were aged ≥65 years, not institu-
tionalized, expected to remain in the current community
for ≥3 years, not under active cancer treatment, and able
to give written informed consent. Follow-up examinations
were done at annual visits through 1998/99 and again in
2006/07. Interviews were also conducted through bian-
nual telephone calls. The study was approved by the
institutional review boards of the 4 clinical sites including:
University of California, Davis (Sacramento County,
Sacramento, CA), Johns Hopkins University (Washington
County, Hagerstown, MD), Wake Forest University
School of Medicine (Forsyth County, Winston-Salem,
NC), University of Pittsburgh (Pittsburgh, PA) [27]. All
participants gave written informed consent including the
use of de-identified samples and data for future analyses.
Measurement of TGF-β
TGF-β1 was measured in 2011–2012 on EDTA-stored
plasma samples from the 1996/97 visit by ELISA (Quan-
tikine Human TGF-β1 Immunoassay; R&D Systems,
Minneapolis, MN). Inter- and intra-assay coefficients of
variation were between 1.9 and 2.9% and 6.4% to 9.3%,
respectively. Platelets are a major source of TGF-β as a
result of platelet degranulation, such that if the plasma is
not platelet poor, platelet contamination in plasma sam-
ples can artificially increase levels of TGF-β [28]. Pre-
sumed platelet contamination of the plasma resulting in
elevated levels of TGF-β was found in pilot studies at
two of the study sites. Therefore, TGF-β was only mea-
sured a priori in 1722 participants at the two remaining
sites and our final analysis included these individuals. Of
the two sites at which TGF-β was not measured, one site
(Washington County, Maryland) did not enroll an
African American cohort in 1992–1993, leading to mod-
est differences in other participant characteristics across
clinic sites.
Kidney function measurements
Blood samples were collected after an overnight fast and
stored at −70 °C using standardized protocols at the
1996/97 visit for the baseline measurements and the
2006/07 for the longitudinal analysis of kidney disease
progression. The primary outcome of interest was
kidney function estimated by serum cystatin C and albu-
minuria. Cystatin C was measured using a particle-
enhanced immunonephelometric assay with a BN II
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nephelometer on plasma specimens (N Latex Cystatin C;
Dade Behring (now Siemens Health-care Diagnostics
Inc.), Deerfield, IL, USA) [29]. The assay range was
0.195–7.330 mg/L, with the reference range for young,
healthy individuals reported as 0.53–0.95 mg/L. For
cystatin C, intra-assay coefficients of variation (CVs)
range from 2.0 to 2.8% and inter-assay CVs range from
2.3 to 3.1%. Glomerular filtration rate (GFR) was calcu-
lated using the CKD-EPI cystatin C equation [30]. GFR
expressed as mL/min per 1.73 m2 of body surface area,
and serum cystatin C expressed in mg/L. In categorical
analyses, CKD was defined as eGFR <60 mL/min/
1.73 m2. In addition, in the longitudinal analysis we eval-
uated change in eGFR from the 1996/97 visit to the
2006/07 visit as an outcome since the measurements of
kidney function were repeated in a subset of survivors at
this time. Albuminuria was assessed using urinary ACR
calculated from spot urinary albumin and creatinine
levels. Albuminuria was defined as ACR ≥30 mg/g in
categorical analyses.
Cardiovascular disease and mortality
CHS has previously reported on the association between
plasma TGF-β levels and cardiovascular disease, includ-
ing heart failure, myocardial infarction, and stroke
through 2010 [31]. It had similarly reported on the asso-
ciation between TGF-β and mortality in another manu-
script [32]. Here, we report on the association between
plasma TGF-β levels and cardiovascular events and mor-
tality in longitudinal analysis considering the longer
duration of follow-up available since our previous publi-
cations (2014) [31, 32]. Participants were followed from
the baseline visit (1996/97 for this analysis) until death,
loss to follow-up, and the end of follow up on December
31st, 2014. Cardiovascular events (including heart failure,
myocardial infarction, and stroke) and death were adju-
dicated by the CHS outcome-assessment committee on
the basis of patient reports, physician diagnoses, medical
records, and medication use [33, 34].
Covariate assessment
We used covariate measurement from the 1996/97 visit.
Age, sex, race, and smoking history variables were col-
lected by self-report. Smoking history was determined
by questionnaire and categorized as current, former, or
never. Blood pressure (BP) was measured twice in seated
position after 5 min rest using standard mercury sphyg-
momanometer. Hypertension was defined by average
seated systolic blood pressure ≥140 mmHg, diastolic
blood pressure ≥90 mmHg, or by the current use of an-
tihypertensive medications. We defined diabetes mellitus
by use of oral hypoglycemic agents or insulin, or as a
fasting glucose level ≥126 mg/dL. Height (m) and
weight (kg) were measured to calculate body mass
index (BMI: kg/m2). Low density lipoprotein (LDL)-
cholesterol and triglycerides were measured during
CHS year 5 (1992–1993) visit. Serum triglyceride levels
were measured with the Olympus Demand System (Olym-
pus, Lake Success, NY, USA); LDL-cholesterol concentra-
tions were calculated by the Friedewald equation [35]. C-
reactive protein (CRP) was measured by an enzyme linked
immunosorbent (ELISA) assay. Prevalent cardiovascular
disease (CVD) was defined by history of myocardial in-
farction, angina, or stroke.
Statistical analysis
Clinical characteristics are presented overall and by quar-
tiles of plasma TGF-β. Continuous data are presented as
mean ± standard deviation (SD), and categorical variables
as counts (%). Variables with skewed distribution are
shown as median (inter quartile range, IQR). Covariates
were compared across plasma TGF-β quartiles using a lin-
ear trend test, and chi-square test for categorical variables.
TGF-β was skewed, so in continuous variable analyses it
was log base 2-transformed so that the β estimates can be
interpreted as per doubling of TGF-β. Correlations were
assessed with Pearson correlation coefficient. To evaluate
whether plasma levels of TGF-β are associated with kid-
ney function we first conducted cross-sectional linear re-
gression analysis with plasma TGF-β as the predictor
variable and kidney function measures (eGFR and log2
ACR) as the outcome variables. To examine whether
TGF-β levels correlated with clinically significant CKD,
we conducted logistic regression analysis for TGF-β and
estimated GFR <60 mL/min/1.73 m2, and subsequently
for TGF-β and ACR ≥30 mg/g. Considering the potential
bias of eGFR equations in the diagnosis of CKD between
eGFR 45–59 mL/min/1.73 m2, we also evaluated the asso-
ciation between TGF-β levels and CKD defined as eGFR
<45 mL/min/1.73 m2 [36]. Several models were applied
for multivariate adjustment. M1 adjusted for age, gender,
and black race. M2 adjusted for the covariates in M1 as
well as BMI, hypertension, DM, smoking status, LDL-
cholesterol, triglycerides, previous history of CVD, and
log2 CRP. Additionally, we adjusted for estimated GFR to-
gether with the covariates included in M2 (when evaluat-
ing the association with ACR) or ACR (when evaluating
the association with eGFR). To evaluate whether baseline
TGF-β predicted kidney disease progression, we con-
ducted a similar analysis longitudinally. Only a subset of
survivors (n = 478) had cystatin C measurements at the
2006/07 visit. Considering this small number, we were un-
able to evaluate whether TGF-β associated with incident
CKD and the designated outcome included change in
CKD-EPI eGFR (from the 1996/97 visit to the 2006/07
visit). Cox proportional hazard models were utilized to
evaluate whether baseline TGF-β levels predicted cardio-
vascular (CV) events, death, or a composite outcome of
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CV events and death. The same covariates included in the
linear regression models were included in the cox propor-
tional hazard models. For all statistical tests, a two-tailed
P-value < 0.05 was considered statistically significant. We
did not adjust for multiple testing. Analyses were con-
ducted using R (R Development Core Team (2015)) [37].
Results
Clinical characteristics of the participants
TGF-β levels were available for 1722 (39%) individuals
out of a total cohort of 4413 at CHS year 9 (1996/97)
visit. ACR values were available for 1541 (89.5%) of par-
ticipants with TGF-β levels. Participants with TGF-β
measurements differed from those without available
measures in several ways. They were younger, more fre-
quently male and black, and had lower blood pressure.
In addition, as shown in Additional file 1: Table S1, they
less often had prevalent CVD. Among those with avail-
able TGF-β levels, the median (IQR) of TGF-β levels
was 3482 (2042–6153) ng/L.
The participant characteristics by TGF-β quartiles at
baseline are shown in Table 1. Compared to participants in
the lower TGF-β quartiles, those with TGF-β levels in the
highest quartile were more frequently black, were more
likely to have DM, to have higher CRP, and to be current
smokers. Age and previous history of CVD were not signifi-
cantly different according to TGF-β quartiles. eGFR was
significantly lower in quartiles 2, 3, and 4 compared to
quartile 1. Albuminuria did not differ significantly among
the groups. Of note, median TGF-β was 3482 (IQR 2042–
6153) for all the participants. Median TGF-β was higher for
those with eGFR <60 ml/min/1.73 m2 compared to those
with eGFR >60 ml/min/1.73 m2 (3747 [IQR 2278–6431] vs.
3377 [IQR 1962–6075] ng/L), with p value = 0.05 (based on
Mood’s test of medians).
The cross-sectional association between TGF-β levels and
eGFR or ACR as continuous variables
Linear regression analysis revealed that each doubling of
TGF-β was significantly associated with lower eGFR (β
estimate = −1.54; 95% C.I. -2.44, −0.63; p < 0.001), al-
though this was marginally non-significant with respect
to log2 ACR (β estimate = 0.09; 95% C.I. 0, 0.18; p =
0.055) in unadjusted analysis. As shown in Table 2, the
association TGF-β and eGFR was slightly attenuated but
remained statistically significant after adjusting for
demographics in model 1 (β estimate = −1.41, 95% CI
−2.27, −0.55) and including cardiovascular risk factors in
model 2 (β = −1.18, 95% CI −2.03, −0.32). Additional ad-
justment for ACR yielded a β estimate of −1.07 (95% CI
−1.95, −0.19). Further inclusion of congestive heart fail-
ure and claudication in the model had no influence on
the association between TGF-β and eGFR. In contrast,
the association between TGF-β and ACR was not signifi-
cant after adjustment of demographics or in any of the
other multivariable models. Since the generalized












Age (years) 78 ± 5 78 ± 4 78 ± 5 78 ± 5 78 ± 5 0.22
Gender (male %) 40 38 41 43 38 0.27
Black race (%) 22 20 18 20 31 <0.01
Current smoker 9 11 6.0 9 11 0.01
Diabetes mellitus (%) 16 13 13 17 20 <0.01
Hypertension (%) 59 62 57 56 63 0.14
Prevalent CVD (%) 24 23 24 25 23 0.89












LDL-cholesterol (mg/dL) 83 ± 87 81 ± 86 83 ± 87 87 ± 90 83 ± 88 0.68
Triglycerides (mg/dL) 138 ± 78 136 ± 73 139 ± 76 134 ± 78 143 ± 84 0.43












% with eGFR <60 ml/min/1.73 m2 25 20 27 28 27 0.01
% with ACR ≥30 mg/g 18 15 19 18 21 0.23
Values are expressed as means ± standard deviation or (%) = percent; BMI body Mass Index, GFR glomerular filtration rate, ACR albumin/creatinine ratio,
CRP C-reactive protein, CVD cardiovascular disease. Prevalent CVD was defined by history of myocardial infarction, angina, or stroke
a, bvalues expressed as median (Interquartile range). P-values are from a linear trend test across quartiles for continuous variables and from chi2 test for binary and
categorical variables
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additive model in relation to eGFR showed that the
association tended to plateau above the median value of
TGF-β (Fig. 1 log2 TGF-β corresponds to approximately
4096 ng/L) we also evaluated the association for
quartiles of the biomarker.
When TGF-β levels were modeled as quartiles, we
found that TGF-β levels in quartiles 2, 3, and 4 were sig-
nificantly associated with lower eGFR relative to the first
quartile. In the unadjusted analysis eGFR was lower by
4.55 (95% C.I. -7.14, −1.95), 4.92 (95% C.I. -7.52, −2.32),
and 4.47 (95% C.I. -7.07, −1.88) ml/min/1.73 m2 for quar-
tiles 2, 3, and 4 respectively. These statistically significant
associations were slightly attenuated but remained signifi-
cant after full adjustment (Table 3). We did not find a
significant association between higher TGF-β levels and
urine ACR in any unadjusted or adjusted analyses.
The cross-sectional association between TGF-β levels and
clinically-significant CKD
To determine whether TGF-β levels associated with clin-
ically significant CKD, we evaluated the binary end point
of either eGFR <60 ml/min/1.73 m2 or with ACR
≥30 mg/g in logistic regression analysis. As depicted in
Fig. 2, TGF-β levels in quartiles 2, 3, and 4 were signifi-
cantly associated with CKD defined as eGFR <60 ml/
min/1.73 m2. In unadjusted analysis, compared to the
participants in quartile 1 of TGF-β levels, participants in
quartile 2 had 53% higher odds of eGFR <60 ml/min/
1.73 m2 (95% C.I. 1.11, 2.1), participants in quartile 3
had 60% higher odds of eGFR <60 ml/min/1.73 m2 (95%
C.I. 1.16, 2.2), and participants in quartile 4 had 52%
higher odds of eGFR <60 ml/min/1.73 m2 (95% C.I. 1.11,
2.10). This remained significant for quartiles 2, 3, and 4
after adjusting for demographics and cardiovascular risk
factors with OR of 1.59 (95% C.I. 1.11, 2.28), 1.72 (95%
C.I. 1.20, 2.45), and 1.50 (95% C.I. 1.04, 2.15), respect-
ively. Of note, when CKD was defined as eGFR < 45 ml/
min/1.73 m2 [36], the fully-adjusted ORs for CKD were
3.59 (95% C.I. 1.66, 7.77; p < 0.001), 4.58 (95% C.I. 2.16,
9.68; p < 0.001), and 4.24 (95% C.I. 2.0, 9.02; p < 0.001)
for quartiles 2, 3, and 4 compared to quartile 1. There
was no consistent evidence of an association between
TGF-β quartiles and ACR ≥30 mg/g. Quartile 4 of TGF-
β levels was associated with 34% higher odds of having
ACR ≥30 mg/g compared to quartile 1 in unadjusted
analysis but this was no longer statistically significant
after adjusting for demographic and cardiovascular risk
factors (OR = 1.34, 95% C.I. 0.89, 2.04, p = 0.17).
The association between baseline TGF-β levels and
longitudinal outcomes
To evaluate whether TGF-β levels predicted kidney dis-
ease progression, we evaluated whether doubling of
TGF-β associated with change in eGFR. We found no
association between TGF-β levels at baseline and change
in CKD-EPI eGFR between the years 1996/97 and 2006/
07 in unadjusted or adjusted models. Only 478 individ-
uals had cystatin C measurements at the 2006/07 visit.
Between the 1996/97 visit and the end of follow-up in
2014, 409 out of the studied 1722 participants died with
a median follow up of 10.3 years (IQR 5.7–15.8). Of the
surviving 1312 participants, 411 were reported to have a
CV event and the median follow up was 9.5 years (IQR
5.1-14.5 years). Similar to the previous report [32], doub-
ling of baseline TGF-β was associated with an increased
risk of death. In adjusted analysis, the hazard ratio (HR)
for death was 1.10 (95% C.I. 1.02, 1.13, p = 0.008). This
was somewhat attenuated to a HR of 1.10 (95% C.I. 1.01,
Table 2 Linear regression analysis of the association between
plasma TGF-β (per doubling) and eGFR and ACR
Model eGFR Urinary ACR

















M1: M0 + age, male gender, and black race
M2: M1 + current smoking status, hypertension, diabetes mellitus, body mass
index, LDL-cholesterol, triglycerides, history of cardiovascular disease, and
C-reactive protein
Fig. 1 This illustrates the partially-fitted estimated GFR (eGFR) when
using splines for TGF-β levels in Generalized Additive Models (GAM)
adjusting for age, sex, black race, smoking, hypertension, diabetes
mellitus, body mass index, LDL-cholesterol, triglycerides, history of
cardiovascular disease, and C-reactive protein. The dotted lines are
the 95% confidence bands. The x axis is on log2 scale and the three
vertical lines show Q1, median, and Q3 of TGF-β
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1.10, p = 0.019) and 1.10 (95% C.I. 1.0, 1.12, p = 0.05) for
model 1 and model 2, respectively. Also similar to the pre-
vious report [31], we found no association between base-
line TGF-β levels and CV events in unadjusted analysis
(HR was 1.10, 95% C.I. 0.99, 1.20, p = 0.074). After adjust-
ing for the covariates included in model 2, doubling of
TGF-β carried a HR of 1.10 for CV events (95% C.I. 1.0–
1.22, p = 0.05). Doubling of baseline TGF-β was associated
with higher risk of the composite outcome of CV events
or death. The unadjusted HR for the composite outcome
1.10 (95% C.I. 1.02, 1.20, p = 0.005). This association
remained significant with HR of 1.10 (95% C.I. 1.03, 1.20,
p = 0.004) and 1.10 (95% C.I. 1.02, 1.20, p = 0.006) for
model 1 and model 2, respectively.
Discussion
In this cross-sectional analysis of community-living older
adults, higher levels of circulating TGF-β were associ-
ated with both lower eGFR as a continuous variable, and
with CKD defined as eGFR <60 mL/min/1.73 m2. We
found no association between TGF-β levels and albu-
minuria. The associations between TGF-β and eGFR
were independent of demographic and cardiovascular
risk factors, C-reactive protein, and albuminuria. In
addition, the association between TGF-β levels and
eGFR was similar in quartiles 2, 3, and 4 when compared
to quartile 1, suggesting that plasma TGF-β above a
threshold may be a risk factor for CKD in older adults.
The association between TGF-β levels and clinically-
significant CKD persisted even when CKD was defined
as <45 mL/min/1.73 m2 suggesting that higher TGF-β
levels are indicative of CKD, not merely an aging kidney
[36]. Thus, we provide new insights to biology associated
with CKD in older community dwelling adults, and find
that measurement of circulating TGF-β may give in-
sights to kidney disease in this setting. We were not able
to find an association between baseline TGF-β levels and
change in eGFR between the 1996/97 and the 2006/07
visits. This is likely due to small number of individuals
with available kidney function measurement as well as
the competing outcomes of CV events and mortality as
TGF-β levels were associated with the composite out-
come of CV events and mortality over an extended
period of follow up.
Table 3 Linear regression analysis of the association between TGF-β quartiles and eGFR and urinary ACR
Quartile 1
β estimate (95% CI)
Quartile 2
β estimate (95% CI)
Quartile 3
β estimate (95% CI)
Quartile 4
β estimate (95% CI)
eGFR
M0 REF –4.55 (–7.14,–1.95) –4.92 (–7.52,–2.32) –4.47 (–7.07,–1.88)
M1 REF –3.8 (–6.26,–1.34) –4.02 (–6.48,–1.56) –4.36 (–6.83,–1.89)
M2 REF –4.57 (–7,–2.14) –4.68 (–7.09,–2.27) –3.86 (–6.28,–1.44)
Urinary ACR
M0 REF 0.24 (–0.02,0.5) 0.21 (–0.06,0.47) 0.25 (–0.01,0.51)
M1 REF 0.21 (–0.05,0.47) 0.16 (–0.1,0.42) 0.18 (–0.08,0.44)
M2 REF 0.25 (0,0.5) 0.20 (–0.05,0.45) 0.15 (–0.1,0.4)
M0: unadjusted analysis
M1: M0 + age, male gender, and black race
M2: M1 + current smoking status, hypertension, diabetes mellitus, body mass index, LDL-cholesterol, triglycerides, history of cardiovascular disease, and
C-reactive protein
Fig. 2 Cross-sectional association between TGF-β quartiles and CKD
defined as eGFR <60 mL/min/1.73 m2. Quartiles 2, 3, and 4 were
compared to quartile 1. The shown adjusted odds ratio are adjusted
for age, sex, black race, smoking, hypertension, diabetes mellitus,
body mass index, LDL-cholesterol, triglycerides, history of cardiovascular
disease, and C-reactive protein: Quartile 2: OR for CKD was 1.59 (95%
C.I. 1.11, 2.28; p value = 0.01) Quartile 3: OR for CKD was 1.72 (95% C.I.
1.20, 2.45; p value = 0.003). Quartile 4: OR for CKD was 1.50 (95% C.I.
1.04, 2.15; p value = 0.03)
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TGF-β is pleiotropic cytokine involved in kidney dis-
ease progression as in vivo experimental studies have
shown renal TGF-β overproduction by mesangial cells
[38], tubular epithelial cells [39], interstitial fibroblasts,
and macrophages [40, 41]. Induction of TGF-β has been
shown to cause extracellular matrix accumulation in the
glomeruli and interstitium [3] leading to progressive kid-
ney disease [4–6]. Consistently, inhibition of TGF-β via
anti-TGF-β antibody has been shown to attenuate fibro-
sis in animal models of kidney disease [7–9]. TGF-β
expression has been demonstrated in the kidneys of indi-
viduals with glomerular disease such as diabetic ne-
phropathy [10, 11], focal segmental glomerulosclerosis
secondary to human immunodeficiency virus (HIV)
infection [12], and other glomerulonephritides such as
IgA nephropathy, and lupus [13]. However, no study to
date has examined whether TGF-β levels are elevated in
older adults, a population at high risk for CKD.
Plasma levels of TGF-β have been measured in 2 stud-
ies in subjects with diabetic kidney disease. Wong et el.
measured plasma TGF-β levels in participants of the
Action in Diabetes and Vascular Disease: Preterax and
Diamicron MR Controlled Evaluation (ADVANCE) trial.
(The study compared the effect of perindopril and inda-
pamide on macrovascular and microvascular outcomes
in patients with type 2 DM) [14]. In a post-hoc analysis
they identified 102 participants with progressive diabetic
kidney disease over a period of 5 years and compared
them to 179 participants whose kidney disease did not
progress. Kidney disease progression was defined as
doubling of serum creatinine, need for renal replacement
therapy, or death due to renal disease during the 5-year
follow up period. They found that baseline TGF-β levels
were higher in participants with progressive kidney
disease compared to the participants whose kidney dis-
ease did not progress. The association between baseline
TGF-β levels and kidney disease progression here was
independent of baseline eGFR and albuminuria. In the
other study of subjects with diabetic nephropathy
Sharma et al. measured TGF-β levels in participants ran-
domized to placebo (n = 24) or captopril (n = 34). Here
kidney disease progression, defined as loss of GFR, was
slower in those whose TGF-β levels were reduced over a
period of 6 months [15]. Collectively, these data suggest
that higher TGF-β levels are associated with progressive
diabetic nephropathy.
In contrast to the aforementioned studies, a recent
cross-sectional analysis by Gupta et al. evaluated TGF-β
levels in 3791 of the Chronic Renal Insufficiency Cohort
(CRIC) participants, almost half of whom had DM. The
investigators found no correlation between TGF-β levels
and measures of kidney function including eGFR or
urinary ACR [16]. Compared to the participants in-
cluded in our analysis, participants in CRIC were
younger, had a higher prevalence of HTN and DM, in
addition to lower eGFR. It is possible that circulating
TGF-β is a more sensitive marker of CKD in older adults
who have a higher prevalence of arterial stiffness. This is
consistent with the role arterial stiffness plays in CKD in
the elderly [21] and considering that TGF-β is induced
in the arterial wall with aging [24].
We found no association between plasma levels of
TGF-β and albuminuria in our population of older
adults. TGF-β is known to affect the glomerular base-
ment membrane in several ways that lead to increased
proteinuria such as induction of podocyte and endothe-
lial to mesenchymal transition and glomerular basement
membrane thickening [42]. Based on this, we expected
that increased TGF-β levels would associate with albu-
minuria. It is possible, however, that increased TGF-β
levels in our study are the result of induced production
in tissues other than the kidney such as the vasculature.
As such, systemic levels of TGF-β may not accurately re-
flect TGF-β production in the kidney. This is consistent
with our previous work that TGF-β levels are associated
with peripheral vascular disease [23] and with our find-
ings in this analysis that TGF-β levels are associated with
the composite end point of CV events/mortality.
There are several limitations to our study. First, the as-
sociation between TGF-β and eGFR is cross-sectional so
we are unable to draw conclusions on the direction of
associations. Although it is unknown whether TGF-β is
filtered by the kidney in humans animal data suggest
that TGF-β is predominantly cleared by the liver [43]. In
addition, although some studies have described forms of
TGF-β with small molecular weight (for example 12.5,
25, 50, and 90 kDa in breast cancer tissue [44]), in
humans, TGF-β is known to be synthesized and secreted
in a biologically latent form as a high-molecular weight
complex (135 kD) that is highly unlikely to be filtered in
the absence of proteinuric glomerular disease [45, 46].
Thus, while our data cannot determine whether high
TGF-β is associated with future decline in kidney func-
tion or if low eGFR raises TGF-β, we hypothesize the
former association on the basis of these prior studies.
Future studies with longitudinal data are an important
next step in this area of research. Second, plasma levels
of TGF-β were measured at a single time point on
stored samples. It is unclear whether TGF-β is stable
over an extended period of time and it is unknown
whether plasma TGF-β levels exhibit inter and intra-
subject variability over time, or whether intra-individual
changes over time are associated with longitudinal
changes in kidney function. In addition, we cannot guar-
antee the complete absence of platelet contamination at
the sites included in this analysis, although we believe
this is unlikely since we conducted pilot studies at all
sites to evaluate this. Of note, we identified potential
Mehta et al. BMC Nephrology  (2017) 18:98 Page 7 of 9
platelet contamination at 2 sites and excluded all the
samples collected at both sites. Finally, because of the
observational nature of the study, we cannot eliminate
the possibility of residual confounding by imprecisely
measured risk factors or unmeasured risk factors.
Notwithstanding these weaknesses, the study has several
strengths including the consistency of TGF-β measure-
ment across samples and the large number of partici-
pants from a community-based cohort.
Conclusions
In this analysis, we show for the first time that higher
levels of plasma TGF-β are independently associated
with lower eGFR and higher prevalence of CKD among
community-dwelling older adults. We observed no
statistically significant association of TGF-β with albu-
minuria. The lack of an association with GFR decline in
our population is likely a reflection of the small number
of participants with follow up kidney function measure-
ments and the competing risk of other outcomes such as
CV events and mortality. Our findings suggest that
increased TGF-β may be a marker of vascular disease
that contributes to GFR decline, CV events, and mortal-
ity in the aged. Future longitudinal studies are needed to
assess whether circulating TGF-β levels are associated
with more rapid loss of kidney function over time in
community-living older adults, and whether therapies
that lower TGF-β and fibrosis may play a role in
preventing or treating CKD and CKD-associated co-
morbidities in older adults.
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